These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
46. [Clinical experience with Catapresan]. Laux L; Angelmann W Med Monatsschr; 1967 Apr; 21(4):186-7. PubMed ID: 5584446 [No Abstract] [Full Text] [Related]
47. [Evaluation of the anti-hypertensive effectiveness of Catapresan (ST-155)]. Ambrosioni E; Corbara F; Perri G G Clin Med; 1971 Mar; 52(3):247-65. PubMed ID: 5121120 [No Abstract] [Full Text] [Related]
48. Moxonidine for hypertension. Drug Ther Bull; 1997 May; 35(5):33-6. PubMed ID: 9282418 [TBL] [Abstract][Full Text] [Related]
49. [Long-term clinical study and serial determination of urinary catecholamines using the new antihypertensive agent ST-155]. Villalpando J; Skromme D; Chávez B; Serrano P Arch Inst Cardiol Mex; 1968; 38(6):841-50. PubMed ID: 5711376 [No Abstract] [Full Text] [Related]
50. [Continuous automatic recording of blood pressure after administration of a new antihypertensive substance]. Haan D Arzneimittelforschung; 1966 Sep; 16(9):1180-3. PubMed ID: 6014739 [No Abstract] [Full Text] [Related]
51. [Angiotensin-2 receptor blockade--new therapeutic approach to treatment of hypertension]. Zimlichman R Harefuah; 1996 Jul; 131(1-2):43-5. PubMed ID: 8854479 [No Abstract] [Full Text] [Related]
52. [New, in Austria registered specialty drugs. Normoxin (moxonidine)]. Kögler H; Raneburger J Wien Klin Wochenschr; 1993; 105(3):94-6. PubMed ID: 8447129 [No Abstract] [Full Text] [Related]
53. [Controlling blood pressure by centrally acting drugs--still a topic?]. Steckelings UM; Unger T Fortschr Med; 1994 Jan; 112(3):25-6. PubMed ID: 8144121 [No Abstract] [Full Text] [Related]
54. [The effect of an imidazole derivative on arterial blood pressure, hemodynamics and ventilation]. Kochsiek K; Fritsche H Arzneimittelforschung; 1966 Sep; 16(9):1154-60. PubMed ID: 6014733 [No Abstract] [Full Text] [Related]
55. [Clinical studies on the antihypertensive effect of Catapresan]. Kreuziger H; Brehm H Med Welt; 1968 Apr; 14():905-7. PubMed ID: 5718198 [No Abstract] [Full Text] [Related]
56. [Stroke prevention. Is there an added value to RAS inhibition?]. MMW Fortschr Med; 2000 Feb; 142(6):62-3. PubMed ID: 10832360 [No Abstract] [Full Text] [Related]
57. Angiotensin II antagonism: a new avenue of hypertension management. Gavras H Blood Press Suppl; 1997; 1():42-6. PubMed ID: 9285108 [TBL] [Abstract][Full Text] [Related]
58. [Long-term antihypertensive therapy with moxonidine (cynt) in patients with insulin-independent diabetes mellitus]. Lazebnik LB; Malichenko SB; Serebrov AN Ter Arkh; 1997; 69(6):59-64. PubMed ID: 9297279 [No Abstract] [Full Text] [Related]
59. [The first clinical experience in Italy with angiotensin II receptor antagonists: results of a multicenter study on the efficacy and tolerance in arterial hypertension]. Trimarco B Cardiologia; 1995 Dec; 40(12 Suppl 1):193-5. PubMed ID: 8998714 [No Abstract] [Full Text] [Related]
60. Observations on the hypotensive action of "Catapres" (ST 155) in man. Barnett AJ; Cantor S Med J Aust; 1968 Jan; 1(3):87-91. PubMed ID: 4867515 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]